Drug intelligence / Profile preview

BITT311

Development stage: Preclinical
Lead developer: Boston Immune Technologies and Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Parenteral, Intravenous, Subcutaneous

Overview

BITT311 is a proprietary monoclonal antibody trap (TrapMAb) targeting CD40, a member of the tumor necrosis factor receptor (TNFR) superfamily. Developed by Boston Immune Technologies and Therapeutics (BITT) in collaboration with Otsuka Pharmaceutical, BITT311 is designed to modulate T-dependent B-cell responses, which are central to the pathogenesis of various autoimmune and inflammatory disorders. The TrapMAb platform utilizes a unique binding architecture to effectively neutralize the target. BITT311 is currently in the IND-enabling phase of development for the treatment of autoimmunity and inflammation.

Targets

CD40 (Cluster of differentiation 40 receptor)

Beyond the preview

Go deeper on BITT311.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BITT311.

Explore the full profile